Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 30

  • 497 clinical trials
  • 183 recruiting
  • 211 conditions
  • 25 countries

Conditions in this area

211 conditions with trials, the busiest first

Type 2 diabetes mellitus83Type 1 diabetes mellitus38Endocrine ophthalmopathy26Neuroblastoma26Obesity22Diabetes mellitus21Neuroendocrine tumour19Gastroenteropancreatic neuroendocrine tumour disease16Overweight16Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Chronic kidney disease8Adrenoleukodystrophy7Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+187

Clinical trials in Endocrine disorders

497 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

497 clinical trials

Myotonic dystrophy

Not recruiting

Study on AOC 1001 for Treating Myotonic Dystrophy Type 1 in Patients

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
  • Sponsor:Avidity Biosciences Inc.

Wolfram syndrome

Not recruiting

Study on Tirzepatide for Improving Insulin Production in Patients with Wolfram Syndrome Type 1

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tirzepatide
  • Sponsor:Ospedale San Raffaele S.r.l.

Neuroblastoma

Not recruiting

Study of LY3295668 Erbumine for Patients with Relapsed or Refractory Neuroblastoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:(2R,4R)-1-(3-Chloro-2-Fluorobenzyl)-4-((3-Fluoro-6-((5-Methyl-1H-Pyrazol-3-Yl)Amino)Pyridin-2-Yl)Methyl)-2-Methylpiperidine-4-Carboxylic Acid
  • Sponsor:Eli Lilly & Co.

Diabetes mellitus

Not recruiting

Study of Metformin Treatment to Maintain Type 2 Diabetes Remission in Patients After Bariatric Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Metformin Embonate
  • Sponsor:Assistance Publique Hopitaux De Paris

Diabetic retinal oedema+1

Not recruiting

Study on Aflibercept for Adults with Diabetic Macular Edema or Wet Age-Related Macular Degeneration

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Neuroblastoma+1

Not recruiting

Study of Palbociclib with Drug Combinations for Children and Young Adults with Recurrent or Refractory Neuroblastoma and Ewing Sarcoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Palbociclib
  • Sponsor:Pfizer Inc.

Erdheim-Chester disease+3

Not recruiting

Study on the Use of Fludeoxyglucose (18F) in PET/CT Scans for Young Patients with Histiocytosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Fludeoxyglucose (18F)
  • Sponsor:Instytut Matki I Dziecka

Erdheim-Chester disease+3

Not recruiting

Study on Trametinib Dimethyl Sulfoxide for Children with Refractory Histiocytosis Not Responding to Conventional Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Trametinib Dimethyl Sulfoxide
  • Sponsor:Instytut Matki I Dziecka

Erdheim-Chester disease+3

Not recruiting

Study on Vemurafenib for Children with BRAF Mutation-Resistant Histiocytosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Vemurafenib
  • Sponsor:Instytut Matki I Dziecka

Neuroendocrine tumour

Not recruiting

Study of Cabozantinib in Adults with Advanced Low-Grade Neuroendocrine Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Universitaetsmedizin Goettingen

Type 2 diabetes mellitus

Not recruiting

Comparison of dapagliflozin versus metformin treatment in patients with early stage type 2 diabetes to evaluate survival and complications

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin Propanediol
  • Sponsor:Uppsala University

Type 1 diabetes mellitus

Not recruiting

Study on the Effects and Safety of Ladarixin for Adults and Adolescents with Recent Onset Type 1 Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Ladarixin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide46 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsSodium Chloride13 clinical trialsCisplatin12 clinical trialsEtoposide12 clinical trialsMetformin Hydrochloride12 clinical trialsCarboplatin11 clinical trialsInsulin Glargine11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.